Literature DB >> 8760038

Increased sensitivity to 1,25(OH)2D3 in bone from genetic hypercalciuric rats.

N S Krieger1, V M Stathopoulos, D A Bushinsky.   

Abstract

As a model of human hypercalciuria, we have selectively inbred genetic hypercalciuric stone-forming (GHS) Sprague-Dawley rats whose mean urine calcium excretion is eight to nine times greater than that of controls. A large component of this excess urine calcium excretion is secondary to increased intestinal calcium absorption, which is not due to an elevation in serum 1,25(OH)2D3, but appears to result from an increased number of intestinal 1,25(OH)2D3 receptors (VDR). When GHS rats are fed a low-calcium diet, the hypercalciuria is only partially decreased and urine calcium excretion exceeds intake, suggesting that an additional mechanism contributing to the hypercalciuria is enhanced bone demineralization. To determine if GHS rat bones are more sensitive to exogenous 1,25(OH)2D3, we cultured calvariae from neonatal (2- to 3-day-old) GHS and control rats with or without 1,25(OH)2D3 or parathyroid hormone (PTH) for 48 h at 37 degrees C. There was significant stimulation of calcium efflux from GHS calvariae at 1 and 10 nM 1,25(OH)2D3, whereas control calvariae showed no significant response to 1,25(OH)2D3 at any concentration tested. In contrast, PTH induced similar bone resorption in control and GHS calvariae. Immunoblot analysis demonstrated a fourfold increase in the level of VDR in GHS calvariae compared with control calvariae, similar to the increased intestinal receptors described previously. There was no comparable change in VDR RNA levels as measured by slot blot analysis, suggesting the altered regulation of the VDR occurs posttranscriptionally. That both bone and intestine display an increased amount of VDR suggests that this may be a systemic disorder in the GHS rat and that enhanced bone resorption may be responsible, in part, for the hypercalciuria in the GHS rat.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760038     DOI: 10.1152/ajpcell.1996.271.1.C130

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  28 in total

Review 1.  Bone disease and idiopathic hypercalciuria.

Authors:  Joseph E Zerwekh
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

2.  Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.

Authors:  Viviane Barcellos Menon; Rosa Maria Affonso Moysés; Samirah Abreu Gomes; Aluizio Barbosa de Carvalho; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

3.  Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats.

Authors:  J Yao; P Kathpalia; D A Bushinsky; M J Favus
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Authors:  Nancy S Krieger; John R Asplin; Ignacio Granja; Felix M Ramos; Courtney Flotteron; Luojing Chen; Tong Tong Wu; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 10.121

5.  Determinants of osteopenia in male renal-stone-disease patients with idiopathic hypercalciuria.

Authors:  Emmanuel Letavernier; Olivier Traxer; Michel Daudon; Mohammed Tligui; Jérôme Hubert-Brierre; Dominique Guerrot; Aline Sebag; Laurent Baud; Jean-Philippe Haymann
Journal:  Clin J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 8.237

6.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

7.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

8.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

9.  Vitamin D receptor gene polymorphism in hypercalciuric children.

Authors:  Oğuz Söylemezoğlu; Ozan Ozkaya; Sevim Gönen; Müge Misirlioğlu; Süleyman Kalman; Necla Buyan
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

Review 10.  Pharmacology of stone disease.

Authors:  Khashayar Sakhaee
Journal:  Adv Chronic Kidney Dis       Date:  2009-01       Impact factor: 3.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.